Skip to main content
. 2020 May 26;9(6):1605. doi: 10.3390/jcm9061605

Table 1.

Patient characteristics.

Desflurane (n = 60) Propofol (n = 58) Spinal (n = 58) p-Value
Age (years) 79.4 ± 7.7 80.5 ± 6.7 81.6 ± 6.7 0.234
Male 13 (21.7%) 16 (27.6%) 17 (29.3%) 0.611
Body mass index (kg/m2) 22.5 (20.0, 24.8) 22.3 (19.6, 24.8) 22.8 (20.4, 25.1) 0.787
Comorbidities
Dementia 12 (20.0%) 7 (12.1%) 10 (17.2%) 0.500
Previous CVA 17 (28.3%) 14 (24.1%) 11 (19.0%) 0.490
CAD 15 (25.0%) 14 (24.1%) 12 (20.7%) 0.843
COPD 2 (3.3%) 1 (1.7%) 5 (8.6%) 0.175
DM 24 (40.0%) 25 (43.1%) 18 (31.0%) 0.380
Hypertension 44 (73.3%) 43 (74.1%) 45 (77.6%) 0.853
Renal dysfunction 8 (13.3%) 12 (20.7%) 13 (22.4%) 0.405
Baseline NT-proBNP 267 (147, 747) 404 (140, 1022) 250 (168, 631) 0.642
Type of fracture 0.170
Femoral neck 26 (43.3%) 26 (44.8%) 36 (62.1%)
Intertrochanteric 27 (45.0%) 29 (50.0%) 21 (36.2%)
Subtrochanteric 3 (5.0%) 1 (1.7%) 0
Other 4 (6.7%) 2 (3.4%) 1 (1.7%)
Time from injury to surgery (h) 78.5 (46.8, 150.5) 58.0 (39.3, 138.8) 76.0 (52.0, 140.8) 0.278
Time from admission to surgery (h) 46.5 (24.0, 71.0) 42.0 (22.8, 70.0) 47.5 (24.0, 72.0) 0.951

Values are mean ±SD or median (interquartile range, IQR); CVA, cerebrovascular accident; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; NT-proBNP, N-terminal pro-brain natriuretic peptide.